Paper4920133
Biochemical and pharmacological studies with asparaginase in man.
Ohnuma T and 3 others. Cancer Res, 1970. Cited by 144 papers, by iCite.
Cite this record
ConductScience Library. Biochemical and pharmacological studies with asparaginase in man. Papers, record 4920133. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4920133
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Asparaginase | Major topic |
| Leukemia | Major topic |
| Metabolic Clearance Rate | Major topic |
| Neoplasms | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Asparagine | |
| Aspartic Acid | |
| Child | |
| Colonic Neoplasms | |
| Escherichia coli | |
| Female | |
| Humans | |
| Leukemia, Lymphoid | |
| Leukemia, Myeloid | |
| Leukemia, Myeloid, Acute | |
| Lymphoma, Non-Hodgkin | |
| Male | |
| Melanoma | |
| Middle Aged | |
| Multiple Myeloma | |
| Neuroblastoma | |
| Osteosarcoma |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 144 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40725166 | Toward Safer Biotherapeutics: Expression and Characterization of a Humanized Chimeric L-Asparaginase in E. coli. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725166 | PubMed |
| 35024306 | Mechanistic studies of PEG-asparaginase-induced liver injury and hepatic steatosis in mice. | Acta Pharm Sin B | 2021 | https://conductscience.org/library/papers/35024306 | PubMed |
| 33876224 | A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. | Blood | 2021 | https://conductscience.org/library/papers/33876224 | PubMed |
| 32703769 | Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32703769 | PubMed |
| 32181110 | Studies on efficient production of a novel l-asparaginase by a newly isolated Pseudomonas resinovorans IGS-131 and its heterologous expression in Escherichia coli. | 3 Biotech | 2020 | https://conductscience.org/library/papers/32181110 | PubMed |
| 31676734 | Metabolic dependencies and vulnerabilities in leukemia. | Genes Dev | 2019 | https://conductscience.org/library/papers/31676734 | PubMed |
| 30302200 | Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. | Int J Hematol Oncol | 2016 | https://conductscience.org/library/papers/30302200 | PubMed |
| 30139388 | Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from Streptomyces brollosae NEAE-115. | BMC Pharmacol Toxicol | 2018 | https://conductscience.org/library/papers/30139388 | PubMed |
| 28330175 | Exploration of the binding modes of L-asparaginase complexed with its amino acid substrates by molecular docking, dynamics and simulation. | 3 Biotech | 2016 | https://conductscience.org/library/papers/28330175 | PubMed |
| 27299599 | A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. | J Pediatr Hematol Oncol | 2016 | https://conductscience.org/library/papers/27299599 | PubMed |
| 26239197 | Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. | Leukemia | 2016 | https://conductscience.org/library/papers/26239197 | PubMed |
| 25210485 | Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. | Clin Med Insights Oncol | 2014 | https://conductscience.org/library/papers/25210485 | PubMed |
| 24905227 | Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties. | PLoS One | 2014 | https://conductscience.org/library/papers/24905227 | PubMed |
| 24014241 | Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. | Blood | 2013 | https://conductscience.org/library/papers/24014241 | PubMed |
| 23961306 | L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. | Am J Case Rep | 2013 | https://conductscience.org/library/papers/23961306 | PubMed |
| 22594522 | L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels. | Drugs R D | 2012 | https://conductscience.org/library/papers/22594522 | PubMed |
| 21505976 | Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells. | J Huazhong Univ Sci Technolog Med Sci | 2011 | https://conductscience.org/library/papers/21505976 | PubMed |
| 21485751 | Depressogenic effects of medications: a review. | Dialogues Clin Neurosci | 2011 | https://conductscience.org/library/papers/21485751 | PubMed |
| 20861736 | Pharmacogenomics in pediatric leukemia. | Curr Opin Pediatr | 2010 | https://conductscience.org/library/papers/20861736 | PubMed |
| 19707421 | First-line treatment of acute lymphoblastic leukemia with pegasparaginase. | Biologics | 2009 | https://conductscience.org/library/papers/19707421 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4920133
GET https://conductscience.org/api/papers/v1/4920133/cited_by?page=2